Magnoliae Flos Extract Inhibits MUC5AC Secretion in COPD
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) lack effective methods to inhibit the expression of MUC5AC and neutrophil infiltration, which are key contributors to the disease's progression and inflammation.
Innovation Solution
A pharmaceutical composition and health functional food utilizing an extract of Magnoliae flos, obtained through methanol extraction and fractionation, which inhibits MUC5AC expression and reduces inflammatory cell infiltration and reactive oxygen species production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for COPD, then general symptom management is achieved, but inhibition of MUC5AC expression and neutrophil infiltration is insufficient
Solution Approach 1:
The patent extracts the active components from Magnoliae flos through systematic fractionation processes (ethyl acetate fractionation, silica gel column chromatography, HPLC purification) to isolate specific compounds responsible for inhibiting MUC5AC expression and neutrophil infiltration, thereby concentrating the therapeutic effect in a defined substance
2Reliability
If Magnoliae flos extract is used to inhibit MUC5AC expression, then anti-inflammatory efficacy is improved, but the extraction and purification process becomes more complex
Solution Approach 1:
The patent segments the complex extraction process into distinct stages: initial ethyl acetate fractionation to separate polar and non-polar components, followed by silica gel column chromatography to further fractionate based on polarity, and finally HPLC purification to isolate individual compounds. This systematic segmentation makes the complex process more manageable and reproducible
Solution Approach 2:
The patent utilizes changes in solvent polarity parameters throughout the fractionation process, progressing from ethyl acetate (moderate polarity) to various eluents in column chromatography with increasing polarity, thereby systematically separating compounds based on their polarity characteristics to isolate the active principles
3Reliability
If Magnoliae flos extract is administered, then neutrophil infiltration and reactive oxygen species production are reduced, but the mechanism of action needs further elucidation
Solution Approach 1:
The patent employs multiple detection methods to monitor the effects of Magnoliae flos extract: ELISA for cytokine quantification, flow cytometry for reactive oxygen species measurement, and histological analysis for inflammatory cell infiltration assessment. These feedback mechanisms provide comprehensive data to elucidate the drug's mechanism of action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Magnoliae flos extract effectively inhibits MUC5AC secretion and neutrophil infiltration, offering a promising treatment for COPD by reducing inflammatory cell infiltration and cytokine levels, comparable to or exceeding the efficacy of existing drugs like roflumilast.
Implementation Method 1
an extract of Magnoliae flos, or a fraction or an active fraction obtained by fractionation thereof with an organic solvent, as described herein
Data Source
Figure 1
Figure 2
Figure 3a
AI summary
The present invention relates to a pharmaceutical composition comprising any of an extract of Magnoliae flos, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient for preventing and treating chronic obstructive pulmonary disease. It was confirmed that the extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-α and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines. Therefore, the extract of Magnoliae flos, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom can be advantageously used as a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease.